Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Yan-Ou Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Corporation, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Antibodies, Monoclonal, Humanized, Neoplasms, Models, Biological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Corporation, Syndax Pharmaceuticals, Incyte.
Abstract (Originalsprache)
Axatilimab, a high‐affinity humanized immunoglobulin G4 monoclonal antibody against colony‐stimulating factor 1 receptor (CSF‐1R), is approved for the treatment of chronic graft‐versus‐host disease (cGVHD), and under investigation for idiopathic pulmonary fibrosis and solid tumors. The population pharmacokinetics (PK) and pharmacodynamics (PD) of axatilimab were characterized in healthy participants and patients with solid tumors or cGVHD using data from four clinical studies with 325 participants, including 278 patients with cGVHD. The model structure reflected the mechanism of action of axatilimab: blocking CSF‐1R signaling with axatilimab reduces the circulating levels of cells in the mononuclear phagocytic cell lineage (including nonclassical monocytic cells (NCMCs) and Kupffer cells), resulting in increases in circulating enzymes owing to reduced clearance by Kupffer cells. The structural model consisted of a two‐compartment axatilimab PK model and turnover PD models for CSF‐1, NCMCs, aspartate transaminase (AST), and creatine phosphokinase (CPK). Axatilimab PK and CSF‐1 equations also included saturable clearance components to reflect the competitive binding of axatilimab and CSF‐1 to CSF‐1R. Covariate search was conducted with the conditional sampling use for the stepwise approach based on correlation tests (COSSAC) approach. Covariate effects on model parameters, steady‐state axatilimab exposure, and NCMC concentrations were assessed. The final population PK/PD model was mathematically described with 6 ordinary differential equations and 39 model parameters. Among the 11 statistically significant covariates, one (body weight) and two (participant population type and baseline CPK) covariates affected axatilimab steady‐state exposure and steady‐state NCMC levels by > 20%, respectively. These results informed the axatilimab dosing strategy in patients with cGVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Incyte Corporation, Wilmington, Delaware, USA.
- M&S Decisions FZ LLC, Dubai, United Arab Emirates.
- Marchuk Institute of Numerical Mathematics RAS, Moscow, Russia.
- Syndax Pharmaceuticals, Inc, Waltham, Massachusetts, USA.
ORCID-Profile: Yan-Ou Yang, Victor Sokolov, Alina Volkova, Cristina Leon
Förderung
- Incyte Corporation
- Syndax Pharmaceuticals
- Incyte
Zitieren
APA
Yang, Y. O., Sokolov, V., Volkova, A., Liu, X., Leon, C., Kosinsky, Y., Barker, B., Zhang, X., Ordentlich, P., Sheng, J., & Chen, X. (2025). Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3503
Vancouver
Yang YO, Sokolov V, Volkova A, Liu X, Leon C, Kosinsky Y, et al. Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3503
BibTeX
@article{Yang2025,
author = {Yang, Yan-Ou and Sokolov, Victor and Volkova, Alina and Liu, Xing and Leon, Cristina and Kosinsky, Yuri and Barker, Breann and Zhang, Xuecheng and Ordentlich, Peter and Sheng, Jennifer and Chen, Xuejun},
title = {Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3503}
}
EUVIMED